Renal Cell Cancer (RCC) Disease Forecast and Market Analysis to 2035

  • ID: 3797427
  • Report
  • Region: Global
  • 300 pages
  • Datamonitor Healthcare
1 of 3
Disease Overview

Renal cell cancer (RCC) is a tumor that originates in the renal cortex, the outer part of the kidney between the renal capsule and the renal medulla. Around 85% of all malignant kidney tumors are RCC, with other types including transitional cell carcinoma of the renal pelvis and Wilms’ tumor (nephroblastoma). The incidence of RCC is higher in those over the age of 60 years, suggesting that the aging population may play a significant role in current and future disease burden. Overall, RCC incidence rates have been steadily increasing in both men and women in the US, Japan, and five major EU markets since the 1970s.

Market snapshot
  • The RCC market will experience moderate growth despite a number of patent expiries of key brands over the forecast period.
  • Sutent continues to be the most widely prescribed therapy in locally advanced and metastatic renal cell cancer.
  • Incident cases of renal cell carcinoma are expected to increase by more than a quarter during 2016-36.
  • Sutent is currently the standard of care for newly diagnosed RCC patients, with Afinitor the standard of care in the second-line setting.
  • Companies are increasingly developing pipeline drugs to use in combination with currently marketed therapies.
Note: Product cover images may vary from those shown
2 of 3
1 FORECAST: RENAL CELL CANCER (Published on 02 March 2017)
  • Executive Summary
  • Market Overview and Trends
  • Methodology And Market Definition
  • AFINITOR (EVEROLIMUS)
  • AVASTIN (BEVACIZUMAB)
  • AVELUMAB
  • CABOMETYX (CABOZANTINIB)
  • INLYTA (AXITINIB)
  • KEYTRUDA (PEMBROLIZUMAB)
  • LENVIMA (LENVATINIB)
  • NEXAVAR (SORAFENIB)
  • OPDIVO (NIVOLUMAB)
  • SUTENT (SUNITINIB)
  • TECENTRIQ (ATEZOLIZUMAB)
  • TORISEL (TEMSIROLIMUS)
  • VOTRIENT (PAZOPANIB)
  • Primary Research Methodology
2 TREATMENT: RENAL CELL CANCER (Published on 16 February 2018)
  • Executive Summary
  • Primary Research Methodology
  • Disease Definition And Diagnosis
  • Patient Segmentation
  • Current Treatment Options
  • Prescribing Trends
3 EPIDEMIOLOGY: RENAL CELL CARCINOMA (Published on 05 February 2018)
  • Executive Summary
  • Disease Background
  • Methodology
  • Forecast
  • Bibliography
  • Appendix: Additional Sources
4 MARKETED DRUGS: RENAL CELL CANCER (Published on 02 March 2017)
  • Executive Summary
  • Product Overview
  • Appendix
5 PRODUCT PROFILE
  • AFINITOR
  • AVASTIN
  • CABOMETYX
  • INLYTA
  • LENVIMA
  • NEXAVAR
  • OPDIVO
  • SUTENT
  • TORISEL
  • VOTRIENT
6 PIPELINE: RENAL CELL CANCER (Published on 02 March 2017)
  • Executive Summary
  • Clinical Pipeline Overview
  • Recently Discontinued Drugs
  • Comparator Therapy
  • Clinical Trial Design
  • Appendix
7 PRODUCT PROFILE (LATE STAGE):
  • KEYTRUDA
  • TECENTRIQ
  • AVELUMAB
List of Figures
Figure 1: Renal cell cancer drug sales in the US, Japan, and five major EU markets, by country, 2015-24
Figure 2: PD-1/PD-L1 drug sales in renal cell cancer in the US, Japan, and five major EU markets, 2015-24
Figure 3: Renal cell cancer drug sales in the US, by status, 2015-24
Figure 4: Renal cell cancer drug sales in Japan, by status, 2015-24
Figure 5: Renal cell cancer drug sales in the five major EU markets, by status, 2015-24
Figure 6: Patient-based forecast methodology for renal cell cancer
Figure 7: Price sources and calculations, by country
Figure 8: Afinitor sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 9: Avastin sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 10: Avelumab sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 11: Cabometyx sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 12: Inlyta sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 13: Keytruda sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 14: Lenvima sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 15: Nexavar sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 16: Opdivo sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 17: Sutent sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 18: Tecentriq sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 19: Torisel sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 20: Votrient sales for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Figure 21: Distribution of renal cell cancer patients across the US, Japan, and five major EU markets, by stage and country
Figure 22: Percentage of Stage I-III renal cell cancer patients receiving each type of treatment, by country
Figure 23: Percentage of Stage IV renal cell cancer patients receiving each treatment type at first-line, by country
Figure 24: Top three regimens used in the first-line treatment of Stage IV renal cell cancer patients, by country
Figure 25: Percentage of Stage IV renal cell cancer patients currently receiving each line of therapy, by country
Figure 26: Top three regimens used in the second-line treatment of Stage IV renal cell cancer, by country
Figure 27: Top three regimens used in the third-line treatment of Stage IV renal cell cancer, by country
Figure 28: Percentage of local-relapse renal cell cancer patients receiving each treatment type at first-line, by country
Figure 29: Percentage of local-relapse renal cell cancer patients receiving neoadjuvant therapy, adjuvant therapy, or both, by country
Figure 30: Top three regimens used in the first-line treatment of local-relapse renal cell cancer patients, by country
Figure 31: Percentage of distant-relapse renal cell cancer patients receiving each treatment type at first-line, by country
Figure 32: Top three regimens used in the first-line treatment of distant-relapse renal cell cancer patients, by country
Figure 33: Percentage of distant-relapse renal cell cancer patients currently receiving each line of therapy, by country
Figure 34: Top three regimens used in the second-line treatment of distant-relapse renal cell cancer patients, by country
Figure 35: Top three regimens used in the third-line treatment of distant-relapse renal cell cancer patients, by country
Figure 36: Trends in incident cases of renal cell carcinoma in the US, Japan, and five major EU markets, 2016-36
Figure 37: Drug assessment summary of key marketed drugs for renal cell cancer
Figure 38: Afinitor for renal cell cancer - SWOT analysis
Figure 39: The author’s drug assessment summary of Afinitor for renal cell cancer
Figure 40: The author’s drug assessment summary of Afinitor for renal cell cancer
Figure 41: Avastin for renal cell cancer - SWOT analysis
Figure 42: The author’s drug assessment summary of Avastin for renal cell cancer
Figure 43: The author’s drug assessment summary of Avastin for renal cell cancer
Figure 44: Cabometyx for renal cell cancer - SWOT analysis
Figure 45: The author’s drug assessment summary of Cabometyx for renal cell cancer
Figure 46: The author’s drug assessment summary of Cabometyx for renal cell cancer
Figure 47: Inlyta for renal cell cancer - SWOT analysis
Figure 48: The author’s drug assessment summary of Inlyta for renal cell cancer
Figure 49: The author’s drug assessment summary of Inlyta for renal cell cancer
Figure 50: Lenvima for renal cell cancer - SWOT analysis
Figure 51: The author’s drug assessment summary of Lenvima for renal cell cancer
Figure 52: The author’s drug assessment summary of Lenvima for renal cell cancer
Figure 53: Nexavar for renal cell cancer - SWOT analysis
Figure 54: The author’s drug assessment summary of Nexavar for renal cell cancer
Figure 55: The author’s drug assessment summary of Nexavar for renal cell cancer
Figure 56: Opdivo pivotal trial data in renal cell cancer
Figure 57: Opdivo for renal cell cancer - SWOT analysis
Figure 58: The author’s drug assessment summary of Opdivo for renal cell cancer
Figure 59: The author’s drug assessment summary of Opdivo for renal cell cancer
Figure 60: Sutent for renal cell cancer - SWOT analysis
Figure 61: The author’s drug assessment summary of Sutent for renal cell cancer
Figure 62: The author’s drug assessment summary of Sutent for renal cell cancer
Figure 63: Torisel for renal cell cancer - SWOT analysis
Figure 64: The author’s drug assessment summary of Torisel for renal cell cancer
Figure 65: The author’s drug assessment summary of Torisel for renal cell cancer
Figure 66: Votrient for renal cell cancer - SWOT analysis
Figure 67: The author’s drug assessment summary of Votrient for renal cell cancer
Figure 68: The author’s drug assessment summary of Votrient for renal cell cancer
Figure 69: Sutent pivotal Phase III trial data in renal cell cancer
Figure 70: Keytruda for renal cell cancer - SWOT analysis
Figure 71: The author’s drug assessment summary of Keytruda for renal cell cancer
Figure 72: The author’s drug assessment summary of Keytruda for renal cell cancer
Figure 73: Tecentriq for renal cell cancer - SWOT analysis
Figure 74: The author’s drug assessment summary of Tecentriq for renal cell cancer
Figure 75: The author’s drug assessment summary of Tecentriq for renal cell cancer
Figure 76: Avelumab for renal cell cancer - SWOT analysis
Figure 77: The author’s drug assessment summary of avelumab for renal cell cancer
Figure 78: The author’s drug assessment summary of avelumab for renal cell cancer

List of Tables
Table 1: Renal cell cancer drug sales in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 2: PD-1/PD-L1 renal cell cancer drug sales in the US, Japan, and five major EU markets, by brand ($m), 2015-24
Table 3: Renal cell cancer drug sales in the US, by brand and status ($m), 2015-24
Table 4: Renal cell cancer drug sales in Japan, by brand and status ($m), 2015-24
Table 5: Renal cell cancer drug sales in the five major EU markets, by brand and status ($m), 2015-24
Table 6: Summary of drug classes and molecules in the renal cell cancer patient-based forecast
Table 7: Exchange rates used for calculating prices
Table 8: Patent expiry dates for key marketed brands in renal cell cancer in the US, Japan, and five major EU markets, 2015-24
Table 9: The author’s estimated launch dates of key late-stage pipeline products and marketed brands in renal cell cancer, 2015-24
Table 10: Afinitor sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 11: Afinitor patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 12: Avastin sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 13: Avastin patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 14: Avelumab sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 15: Avelumab patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 16: Cabometyx sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 17: Cabometyx patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 18: Inlyta sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 19: Inlyta patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 20: Keytruda sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 21: Keytruda patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 22: Lenvima sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 23: Lenvima patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 24: Nexavar sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 25: Nexavar patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 26: Opdivo sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 27: Opdivo patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 28: Sutent sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 29: Sutent patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 30: Tecentriq sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 31: Tecentriq patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 32: Torisel sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 33: Torisel patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 34: Votrient sales for renal cell cancer in the US, Japan, and five major EU markets, by country ($m), 2015-24
Table 35: Votrient patient numbers for renal cell cancer in the US, Japan, and five major EU markets, by country, 2015-24
Table 36: Oncologists and urologists surveyed for the renal cell cancer primary research study, 2015
Table 37: Oncologists and urologists surveyed for the renal cell cancer primary research study, 2017
Table 38: Renal cell cancer five-year survival rates, by stage at diagnosis
Table 39: TNM classification, by stage at diagnosis
Table 40: Leading treatments for renal cell cancer across the US, Japan, and five major EU markets
Table 41: Cancer registry databases used as a source of renal cell carcinoma incidence data, by country
Table 42: Forecasting methodology for renal cell incidence, by country, age group, and gender
Table 43: Sources of survival data used to estimate renal cell carcinoma prevalence, by country
Table 44: Incident cases of renal cell carcinoma in the US, Japan, and five major EU markets, by country, 2016-36
Table 45: Key marketed drugs for renal cell cancer
Table 46: Afinitor drug profile
Table 47: Afinitor pivotal Phase III trial data in renal cell cancer
Table 48: Avastin drug profile
Table 49: Avastin pivotal Phase III trial data in renal cell cancer
Table 50: Cabometyx drug profile
Table 51: Cabometyx pivotal Phase III trial data in renal cell cancer
Table 52: Inlyta drug profile
Table 53: Inlyta pivotal Phase III trial data in renal cell cancer
Table 54: Lenvima drug profile
Table 55: Lenvima pivotal Phase II trial data in renal cell cancer
Table 56: Lenvima ongoing Phase III clinical trial in renal cell cancer
Table 57: Nexavar drug profile
Table 58: Nexavar pivotal Phase III trial data in renal cell cancer
Table 59: Opdivo drug profile
Table 60: Opdivo ongoing Phase III clinical trial in renal cell cancer
Table 61: Sutent drug profile
Table 62: Overview of pivotal Phase III trial data for Sutent in renal cell cancer
Table 63: Sutent ongoing Phase III clinical trial in renal cell cancer
Table 64: Torisel drug profile
Table 65: Torisel pivotal Phase III trial data in renal cell cancer
Table 66: Votrient drug profile
Table 67: Votrient pivotal Phase III trial data in renal cell cancer
Table 68: Votrient Phase III trial data in renal cell cancer
Table 69: Votrient ongoing late-phase clinical trial in renal cell cancer
Table 70: Phase III pipeline products in development for renal cell cancer
Table 71: PD-1/PD-L1 Phase III combination regimens in development for advanced renal cell cancer
Table 72: Late-stage compounds that were recently discontinued for renal cell cancer
Table 73: Sutent drug profile
Table 74: Typical Phase III clinical trial design in renal cell cancer
Table 75: Clinical endpoints that led to the approval of current treatments for renal cell cancer
Table 76: Summary of therapeutic classes in renal cell cancer by ATC code
Table 77: Keytruda drug profile
Table 78: Keytruda Phase III trial in renal cell cancer
Table 79: Tecentriq drug profile
Table 80: Tecentriq Phase III trial in renal cell cancer
Table 81: Avelumab drug profile
Table 82: Avelumab Phase III trial in renal cell cancer
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll